IT Services - Germany



-50.0%

Buy (old: Buy) 25.01.2024

EUR 1.00 (old: EUR 1.00)

One q.beyond to drive margins in 2024e

In light of the ongoing restructuring process as well as macro-headwinds, we observed a rather uninspiring operating performance, especially on the bottom-line, as of 9M '23. Despite that, **q.beyond is seen to achieve its FY** '23 guidance: \in 185-191m sales, \in 5-7m EBITDA and $> \in$ -4m FCF. While the lower end of the sales guidance should be reached (eNuW: \in 186m) and FCF generation should even be positive (eNuW: \in 1.4m), meeting the EBITDA outlook (eNuW: \in 5.1m) still depends on a decision by the tax authorities concerning the Plusnet sale in 2019. The group's operating EBITDA looks set to come in at only \in 0.3m (eNuW).

That said, the company is seen to publish **preliminary FY figures** in early March, (final: March 30th) as well as an initial **FY '24 guidance**. As management aims to **reap the fruits of the imposed efficiency measures in connection with the 2025 Strategy**, investors should expect an outlook, targeting sales growth in the mid-to-high-single-digit range (eNuW: +7%; eCons: +5.4%), positive FCF generation (eNuW: +5.3%), eCons: +5.4%) as well as EBITDA of +6.9% (eNuW: +6.1%).

As a reminder, with the 2025 Strategy, management set itself three strategic priorities: (1) Ongoing focus on key verticals (retail, logistics & manufacturing) coupled with an expansion of the consulting and development business, (2) effective go-to-market with an increased emphasis on the indirect sales channels (35% of Q3 order intake) as well as (3) the continuous implementation of One q.beyond, which is the company's current efficiency program. Here, the focus is on streamlined processes via the elimination of duplicate structures, an optimized order-to-cash process and an increased near-/off-shoring share (target: >20% vs c. 10% currently).


While some of those measures, such as the improved receivables management, already took effect (improved FCF guidance (old: $> \in 8$ m), the implementation of *One q.beyond* is seen to fully unfold from 2024e onwards, thus allowing for expanding margins.

We hence turn cautiously optimistic but keep our **PT unchanged at € 1.00.** While the stock should have downside protection thanks to the € 37m net cash position as well as a land plot in Hamburg (€ 17m book value), an upbeat FY guidance in March as well as a strong start into the year (Q1 to be released on May 8th) could serve as re-rating catalysts. Remains a **BUY**.

Y/E 31.12 (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	143.4	155.2	173.0	186.1	199.1	213.5
Sales growth	-39.8%	8.2%	11.5%	7.5%	7.0%	7.2%
EBITDA	-2.0	31.7	1.4	5.1	6.1	11.6
Net debt (if net cash=0)	-44.9	-54.3	-30.7	-34.6	-39.9	-48.5
FCF	-10.5	-14.9	-4.7	1.4	5.3	8.6
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
EPS pro forma	-0.16	0.08	-0.27	-0.09	-0.03	-0.00
EBITDA margin	-1.4%	20.5%	0.8%	2.7%	3.1%	5.4%
ROCE	-10.1%	9.1%	-23.2%	-7.4%	-4.8%	0.1%
EV/sales	0.2	0.1	0.3	0.2	0.2	0.1
EV/EBITDA	-16.7	0.7	31.7	7.8	5.6	2.2
PER	-3.6	7.4	-2.2	-6.4	-16.5	-337.8
Adjusted FCF yield	-37.8%	136.9%	-23.1%	-0.4%	14.8%	37.1%

Source: Company data, NuWays, Close price as of 23.01.2024

2022



Company description

2021

2020

Source: NuWays Research

Sales (2020-25e)

240.0m

180.0m

120.0m

60.0m

0.0m

q.beyond AG is a German-based digital solutions company, active in the fields of cloud management, system applications and products, IoT, and other IT services. The company operates in several countries with a strong focus on the DACH-region.



Market data	
Share price (in €)	0.58
Market cap (in € m)	71.7
Number of shares (in m pcs)	124.5
Enterprise value (in € m)	34.2
Ø trading volume (6 months)	81,317


12m rel. performance

Ide	ntifier
Bloomberg	QBY GR
Reuters	QSCGF
WKN	513700
ISIN	DE0005137004

Key shareholders	
Gerd Eickers	12.7%
Dr. Bernd Schlobohm	12.7%
Free Float	74.7%

Estimates changes				
	2023e	<u>2024e</u>	<u>2025e</u>	
Sales	0%	0%	0%	
EBIT	0%	0%	0%	
EPS	0%	0%	0%	

Comment on changes



Guidance

- Sales: € 185-191m
- EBITDA: € 5-7m
- FCF: > € -4m

Update - 25.01.2024



Financials

Profit and loss (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	143.4	155.2	173.0	186.1	199.1	2025e 213.5
Sales growth	-39.8%	8.2%	11.5%	7.5%	7.0%	7.2%
Cost of sales	120.3	124.9	145.6	157.3	163.3	170.4
Gross profit	23.2	30.3	27.5	28.8	35.8	43.1
Sales and marketing	12.6	12.6	12.9	13.5	14.3	14.9
General and administration	14.7	17.2	18.7	15.6	15.9	16.5
Research and development	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	2.8	36.3	6.0	5.6	1.0	1.1
Other operating expenses	0.7	5.1	0.5	0.1	0.4	1.1
Total operating expenses	25.1	-1.5	26.1	23.7	29.7	31.5
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	-2.0	31.7	1.4	5.1	6.1	11.6
Depreciation	16.8	16.6	12.3	12.7	9.5	9.4
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	21.0	2.7	2.4	2.1
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	-18.8	15.2	-32.0	-10.4	-5.8	0.1
Interest income	0.1	0.0	0.1	0.2	0.0	0.0
Interest expenses	0.5	0.3	0.2	0.2	0.1	0.1
Investment income	-0.0	-0.3	-0.9	-0.3	-0.3	-0.3
Financial result	-0.5	-0.5	-1.0	-0.3	-0.4	-0.4
Recurring pretax income from continuing operations	-19.3	14.6	-32.9	-10.6	-6.2	-0.3
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	-19.3	14.6	-32.9	-10.6	-6.2	-0.3
Income tax expense	0.6	4.8	0.2	0.6	-1.9	-0.1
Net income from continuing operations	-19.9	9.8	-33.1	-11.2	-4.3	-0.2
Income from discontinued operations (net of tax)	0.0 -19.9	0.0 9.8	0.0 -33.1	0.0 -11.2	0.0 -4.3	0.0 -0.2
Net income Minority interest	0.0	0.1	0.0	0.0	- 4.3 0.0	0.0
Minority interest Net profit (reported)	- 19.9	9.7	-33.1	-11.2	-4.3	-0.2
Average number of shares	124.3	124.5	124.5	124.5	124.5	124.5
EPS reported	-0.16	0.08	-0.27	-0.09	-0.03	-0.00
	0.10	0.00	V.27	0.00	0.00	0.00
Profit and loss (common size)	0000	2021	2022	2022	2024e	
	2020	2021		2023e	20270	2025e
	100.0%	100.0%	100.0%	100.0%	100.0%	2025e 100.0%
Sales Cost of sales						
Sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Sales Cost of sales	100.0% 83.8%	100.0% 80.5%	100.0% 84.1%	100.0% 84.5%	100.0% 82.0%	100.0% 79.8%
Sales Cost of sales Gross profit Sales and marketing	100.0% 83.8% 16.2%	100.0% 80.5% 19.5%	100.0% 84.1% 15.9%	100.0% 84.5% 15.5%	100.0% 82.0% 18.0%	100.0% 79.8% 20.2%
Sales Cost of sales Gross profit Sales and marketing General and administration	100.0% 83.8% 16.2% 8.8% 10.3% 0.0%	100.0% 80.5% 19.5% 8.1%	100.0% 84.1% 15.9% 7.4%	100.0% 84.5% 15.5% 7.3%	100.0% 82.0% 18.0% 7.2%	100.0% 79.8% 20.2% 7.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development	100.0% 83.8% 16.2% 8.8% 10.3% 0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 0.5%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9%	79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 0.5%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0%	79.8% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1%	79.8% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 4.4%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 4.4% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 4.4% 0.0% 1.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% 0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5% 0.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 4.4% 0.0% 1.0% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net)	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 9.8%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5% 0.0% -5.6%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 4.4% 0.0% 1.0% 0.0% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -1.3.1% 0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 9.8% 0.0%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 0.5% 14.8% 0.0% 4.4% 0.0% 1.0% 0.0% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -1.3.1% 0.0% 0.3%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 9.8% 0.0% 0.0%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% 0.0%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 0.5% 14.8% 0.0% 5.4% 0.0% 0.0% 0.0% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -1.3.1% 0.0% 0.3% -0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 4.4% 0.0% 0.0% 0.0% 0.0% -0.2%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -1.3.1% 0.0% 0.3% -0.0% neg.	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% -0.2% neg.	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg.	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg.	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2% neg.	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 0.0% 5.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0
Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -1.3.1% 0.0% 0.3% -0.0% neg13.4%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 0.0% 0.2% -0.2% neg. 9.4%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg5.7%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -2.9% neg3.1%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 0.0% 0.0% 0.0% 0.0% 0.0% -0.2% neg0.1%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg13.4% 0.0%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 0.0% 0.2% -0.2% neg. 9.4% 0.0%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0% 0.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 0.0% 2.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg5.7% 0.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2% neg3.1% 0.0%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0
Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -0.0% 0.0% -13.1% 0.0% neg13.4% 0.0% -13.4%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% -0.2% neg5.7% 0.0% -5.7%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -2.9% neg3.1% 0.0% -3.1%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 4.4% 0.0% 0.0% 0.0% 0.0% 0.0% -0.2% neg0.1%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg13.4% 0.0% -13.4% -3.2%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0% -0.5%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% -0.2% neg5.7% 0.0% -5.5%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -2.9% neg3.1% 0.0% -3.1% 30.0%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 4.4% 0.0% 0.0% 0.0% -0.2% neg0.1% 30.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg13.4% 0.0% -13.4% -3.2% -13.9%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0% -0.5% -19.0% -0.5% -19.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% -0.2% neg5.7% 0.0% -5.5% -6.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -2.9% neg3.1% 0.0% -3.1% 30.0% -2.2%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -13.1% 0.0% -13.1% 0.0% -13.4% 0.0% -13.4% -3.2% -13.9%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3% 6.3%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0% -0.5% -19.0% -19.1%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% -0.2% neg5.7% 6.0% -5.5% -6.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -2.9% neg3.1% 30.0% -2.2% -2.2%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 5.4% 0.0% 0.0% 0.0% 0.0% 0.0% -0.2% neg0.1% 30.0% -0.1%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% 0.0% -1.4% 11.7% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg13.4% 0.0% -13.4% -3.2% -13.9%	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 0.0% 20.5% 10.7% 0.0% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3%	100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.0% 0.8% 7.1% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0% -0.5% -19.0% -0.5% -19.0%	100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% 0.0% 1.5% 0.0% -5.6% 0.1% -0.2% neg5.7% 0.0% -5.5% -6.0%	100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 0.0% 3.1% 4.8% 0.0% 1.2% 0.0% -2.9% 0.0% -2.9% neg3.1% 0.0% -3.1% 30.0% -2.2%	100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 0.0% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0

Source: Company data, NuWays

Update - 25.01.2024



Balance sheet (EUR m)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	52.9	51.9	28.7	27.0	25.6	24.5
Property, plant and equipment	49.0	39.0	37.8	27.9	21.3	15.1
Financial assets	0.2	6.3	5.3	5.3	5.3	5.3
FIXED ASSETS	102.1	97.2	71.8	60.1	52.2	44.9
Inventories	0.1	0.2	0.2	0.3	0.3	0.4
Accounts receivable	37.1	35.4	39.7	40.8	43.6	46.8
Other assets and short-term financial assets	3.5	5.0	4.9	4.9	4.9	4.9
Liquid assets	44.9	56.7	36.4	37.8	43.1	51.7
Deferred taxes	0.0	0.0	0.0	0.0	0.0	0.0
Deferred charges and prepaid expenses	3.2	5.8	8.2	8.2	8.2	8.2
CURRENT ASSETS	88.8	103.1	89.3	91.9	100.1	111.9
TOTAL ASSETS	190.9	200.3	161.1	152.1	152.3	156.7
SHAREHOLDERS EQUITY	136.6	147.1	115.1	110.6	109.0	111.6
	0.0		0.5			
MINORITY INTEREST	6.3	0.3	0.5 2.3	0.5 2.3	0.5	0.5
Provisions for pensions and similar obligations		4.8			2.3	2.3
Other provisions and accrued liabilities	6.8 0.0	4.7	2.4 0.0	2.4	2.4	2.4
Short-term liabilities to banks		0.0		0.0	0.0	0.0
Accounts payable Advance payments received on orders	22.4 0.0	25.4 0.0	24.6 0.0	24.5 0.0	26.2 0.0	28.1 0.0
• •						
Other liabilities (incl. from lease and rental contracts)	17.9 0.3	13.7	7.7 2.2	7.7	7.7	7.7
Deferred taxes	0.3	1.6	2.2 0.5	0.3 0.6	0.3	0.3
Deferred income		0.4	32.4	32.2	0.6	0.6 35.8
CURRENT LIABILITIES TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	40.3 190.9	39.0 200.3	32. 4 161.1	152.1	33.9 152.3	35.0 156.7
TO TAL LIABILITIES AND STIANLITOLDERS EQUIT	150.5	200.0	101.1	102.1	102.0	100.7
Balance sheet (common size)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	27.7%	25.9%	17.8%	17.7%	16.8%	15.6%
Property, plant and equipment	25.7%	19.5%	23.5%	18.3%	14.0%	9.6%
Financial assets	0.1%	3.1%	3.3%	3.5%	3.5%	3.4%
FIXED ASSETS	53.5%	48.5%	44.6%	39.6%	34.3%	28.6%
Inventories	0.0%	0.1%	0.1%	0.2%	0.2%	0.2%
Accounts receivable	19.4%	17.7%	24.6%	26.8%	28.7%	29.9%
Other assets and short-term financial assets	1.8%	2.5%	3.0%	3.2%	3.2%	3.1%
Liquid assets	23.5%	28.3%	22.6%	24.9%	28.3%	33.0%
Deferred taxes	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred charges and prepaid expenses	1.7%	2.9%	5.1%	5.4%	5.4%	5.2%
CURRENT ASSETS	46.5%	51.5%	55.4%	60.4%	65.7%	71.4%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	71.5%	73.4%	71.5%	72.7%	71.6%	71.2%
MINORITY INTEREST	0.0%	0.1%	0.3%	0.3%	0.3%	0.3%
Provisions for pensions and similar obligations	3.3%	2.4%	1.4%	1.5%	1.5%	1.5%
Other provisions and accrued liabilities	3.5%	2.4 %	1.5%	1.6%	1.6%	1.5%
Short-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts payable	11.8%	12.7%	15.3%	16.1%	17.2%	17.9%
. ,	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Advance payments received on orders Other liabilities (incl. from lease and rental contracts)	9.4%	6.8%	4.8%	5.1%	5.1%	4.9%
,						
Deferred taxes Deferred income	0.2%	0.8%	1.3%	0.2%	0.2%	0.2%
	0.3%	0.2%	0.3%	0.4%	0.4%	0.4%
CURRENT LIABILITIES TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	21.1%	19.5%	20.1%	21.2%	22.3% 100.0%	22.8% 100.0%
TOTAL LIADILITIES AND SHAREHULDERS EQUIT	100.0%	100.0%	100.0%	100.0%	100.0%	100.0

Source: Company data, NuWays

Update - 25.01.2024



Ocal flow etatement (FUD as)	0000	0004	0000	0000	0004-	0005-
Cash flow statement (EUR m)	2020	2021	2022	2023e	2024e	2025e
Net profit/loss Depreciation of fixed assets (incl. leases)	-19.9 16.9	9.8 16.2	-33.1 12.3	-11.2	-4.3 9.5	-0.2 9.4
,	0.0	0.0	21.0	12.7 2.7	9.5 2.4	9.4 2.1
Amortisation of goodwill & intangible assets Others	-0.0	0.0	-5.1	0.0	0.0	0.0
Cash flow from operating activities	-13.4	-12.6	-3.1 -11.3	0.0	5.7	9.4
Increase/decrease in inventory	0.0	0.0	0.0	-0.1	-0.0	-0.0
Increase/decrease in accounts receivable	-6.3	2.4	-4.3	-0.1 -1.1	-0.0 -2.9	-3.1
Increase/decrease in accounts payable	0.1	0.5	-0.7	-0.2	1.7	1.9
Increase/decrease in other working capital positions	3.2	-3.5	0.6	0.0	0.0	0.0
Increase/decrease in working capital	-2.9	-0.6	-4.3	-1.4	-1.2	-1.3
Cash flow from operating activities	-5.0	-7.7	-1.3	5.2	9.2	12.8
CAPEX	5.6	7.3	3.5	3.8	4.0	4.2
Payments for acquisitions	1.5	15.5	10.6	0.0	0.0	0.0
Financial investments	0.0	6.4	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	53.8	0.1	0.0	0.0	0.0
Cash flow from investing activities	-7.1	24.7	-14.0	-3.8	-4.0	-4.2
Cash flow before financing	-15.8	17.0	-15.2	1.4	5.3	8.6
Increase/decrease in debt position	-5.7	-5.4	-0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.3	0.2	0.0	0.0	0.0	0.0
Dividends paid	3.7	0.0	0.0	0.0	0.0	0.0
Others	-0.0	0.0	-5.1	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	-9.1	-5.3	-5.1	0.0	0.0	0.0
Increase/decrease in liquid assets	-21.1	11.8	-20.3	1.4	5.3	8.6
Liquid assets at end of period	44.9	56.7	36.4	37.8	43.1	51.7
				01.10		
Key ratios (EUR m)	2020	2021	2022	2023e	2024e	2025e
P&L growth analysis						
Sales growth	-39.8%	8.2%	11.5%	7.5%	7.0%	7.2%
EBITDA growth	-101.4%	-1704.4%	-95.7%	270.9%	21.1%	89.2%
EBIT growth	-121.4%	-180.6%	-310.5%	-67.6%	-43.9%	-101.6%
EPS growth	-127.0%	-148.7%	-440.7%	-66.1%	-61.3%	-95.1%
Efficiency						
Sales per employee	144.4	152.5	148.2	155.6	164.0	170.7
EBITDA per employee	-2.0	31.2	1.2	4.2	5.1	9.3
No. employees (average)	994	1,018	1,167	1,196	1,214	1,250
Balance sheet analysis						
Avg. working capital / sales	4.5%	4.2%	8.7%	7.2%	8.3%	8.4%
Inventory turnover (sales/inventory)	2,516.1	623.1	797.3	600.0	600.0	600.0
Accounts receivable turnover	94.3	83.3	83.7	80.0	80.0	80.0
Accounts payable turnover	68.1	74.2	61.8	48.0	48.0	48.0
Cash flow analysis						
Free cash flow	-10.5	-14.9	-4.7	1.4	5.3	8.6
Free cash flow/sales	-7.4%	-9.6%	-2.7%	0.8%	2.6%	4.0%
FCF / net profit	53.0%	neg.	14.3%	neg.	neg.	neg.
Capex / sales	3.9%	8.8%	2.0%	2.0%	2.0%	2.0%
Solvency						
Net debt	-44.9	-54.3	-30.7	-34.6	-39.9	-48.5
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	0.8%	13.0%	6.8%	6.0%	2.2%	3.1%
Returns	40.40/	0.40/	00.00/	7.40/	4.00/	0.40/
ROCE	-10.1%	9.1%	-23.2%	-7.4%	-4.8%	0.1%
ROE	-14.6%	6.6%	-28.7%	-10.1%	-4.0%	-0.2%
Adjusted FCF yield	-37.8%	136.9%	-23.1%	-0.4%	14.8%	37.1%
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
DPS	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	-0.16	0.08	-0.27	-0.09	-0.03	-0.00
Average number of shares	124.3	124.5	124.5	124.5	124.5	124.5
Valuation ratios	0.5	0.5	0.0	0.0	0.7	0.0
P/BV	0.5	0.5	0.6	0.6	0.7	0.6
EV/sales	0.2	0.1	0.3	0.2	0.2	0.1
EV/EBITDA	-16.7	0.7	31.7	7.8	5.6	2.2
EV/EBIT	-1.8	1.5	-1.4	-3.8	-5.9	278.8
Source: Company data, NuWays						

Update - 25.01.2024



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
q.beyond AG	2

Historical target p	rice and rating changes for q.	beyond AG			
Company	Date	Analyst	Rating	Target Price	Close
q.beyond AG	26.10.2023	Sennewald, Philipp	n.a.	EUR 1.00	EUR 0.58
	14.08.2023	Sennewald, Philipp	n.a.	EUR 1.20	EUR 0.71
	03.03.2023	Sennewald, Philipp	n.a.	EUR 1.30	EUR 0.98

Update - 25.01.2024



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed com-

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 25/01/2024 08:02 AM

Date of publication dissemination: 25/01/2024 08:03 AM

Update - 25.01.2024



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

<u>Instagram</u>



Twitter/X



<u>Linkedlı</u>

